Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCX 191

Drug Profile

OCX 191

Alternative Names: 3-AP; NSC 663249; NSC#663249; NTO-1151; OCX-0191; Triapine

Latest Information Update: 06 Oct 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer National Cancer Institute (USA); Ology Bioservices; Trethera; Vion Pharmaceuticals
  • Class Antineoplastics; Pyridines; Small molecules; Thiosemicarbazones
  • Mechanism of Action Ribonuclease inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical cancer; Gynaecological cancer; Solid tumours
  • Preclinical Leukaemia
  • No development reported Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Haematological malignancies; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Discontinued Cancer; Cancer metastases; Hepatitis B; Herpes simplex virus infections; HIV infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 05 Jan 2017 Preclinical trials in Leukaemia (Combination therapy) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top